Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1563-1570

  Kramar, A ^a   Bachelot, T ^b   Madrange, N ^c   Pierga, J Y ^d   Kerbrat, P ^e   Espie M ^f   Fumoleau, P ^g   Pauporte I ^h   Khayat, D ⁱ   Romieu, G ^j   Pivot, Xavier ^k  

^a CENTRE OSCAR LAMBRET   (France)

^b CENTRE LÉON BÉRARD   (France)

^c INSTITUT BERGONIÉ   (France)

^d INSTITUT CURIE   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g CENTRE GEORGES FRANÇOIS LECLERC   (France)

^h INSTITUT NATIONAL DU CANCER   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j CENTRE VAL D AURELLE   (France)

^k UNIVERSITY HOSPITAL OF BESANÇON   (France)

more..

Author keywords

Adjuvant treatment; Breast cancer; Prognosis; Trastuzumab

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; EPIDEMIOLOGY; FRANCE; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; CANCER GRADING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; HIGH RISK PATIENT; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; RISK ASSESSMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FRANCE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84905176671     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu177     Document Type: Article

References (13)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-1672.
2. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1673-1684.
3. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365(14): 1273-1283.
4. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369(9555): 29-36.
5. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013; 382(9897): 1021-1028.
6. Pivot X, Romieu G, Debled M et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013; 14(8): 741-748.
7. Procter M, Suter TM, de Azambuja E et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010; 28(21): 3422-3428.
8. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25(25): 3859-3865.
9. Russell SD, Blackwell KL, Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28(21): 3416-3421.
10. Untch M, Gelber RD, Jackisch C et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19(6): 1090-1096.
11. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 2006; 354(16): 1667-1669.
12. Simes RJ, Zelen M. Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer. J Clin Oncol 1985; 3(10): 1418-1431.
13. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.